Could a new drug beat the standard for preventing postpartum hemorrhage?
NCT ID NCT06333340
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether carbetocin works better than oxytocin to prevent severe bleeding after a planned C-section in women with risk factors like twins, a large baby, or obesity. About 160 participants will receive one of the two drugs, and doctors will measure how many need extra medication to control bleeding. The goal is to find a more effective option for those at higher risk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Carbetocin and oxytocin
What this could lead to
If carbetocin works better, it could reduce dangerous bleeding after C-sections in high-risk women.
What could go wrong
This is a small, early-phase trial (160 participants) and may not prove carbetocin is superior. Both drugs have known side effects like nausea or low blood pressure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST PARTUM HEMORRHAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mount Sinai Hospital
RECRUITINGToronto, Ontario, M5G1X5, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact